 Alkermes plc NASDAQ: ALKS presented new data from the ongoing phase 12 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 IL-2 variant immunotherapy for advanced renal cell carcinoma RCC. The data were presented at the American Society of Clinical Oncology ASCO Genitourinary GU Cancers Symposium. 